Cancer Epidemiology

All Items

• The National Swedish Lymphoma Register – a systematic validation of data quality

  Karin Ekström Smedby, Sandra Eloranta, Tove Wästerlid, Victor Falini, Urban Jerlström, Fredrik Ellin, Karin Papworth, Johanna Westerberg, Catharina Lewerin, Per-Ola Andersson, Hallgerdur Lind Kristjansdottir, Lena Brandefors, Charlott Mörth, Karin Hallén, Nevzeta Kuric, Amal Abu Sabaa, Björn E. Wahlin, Daniel Molin, Gunilla Enblad, Ann-Sofi Hörstedt, Mats Jerkeman, Ingrid Glimelius

  563-572

• Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland

  Wei Zhang, Arndt A. Schmitz, Roosa E. Kallionpää, Merja Perälä, Niina Pitkänen, Mikko Tukiainen, Erika Alanne, Korinna Jöhrens, Renate Schulze-Rath, Bahman Farahmand, Jihong Zong

  542-551

• Treatment-related mortality in childhood cancer patients – who, when and how much

  Trausti Oskarsson, Fredrik Baecklund

  532-534

• The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer

  Marie-Christina Jahreiß, Luca Incrocci, Katja K.H. Aben, Kim C. de Vries, Mischa Hoogeman, Maartje J. Hooning, Wilma D. Heemsberge

  511-517

• Lung cancer: a nationwide analysis of sex and age incidence trends from 1980 to 2022

  Morten Borg, Hanne Tønnesen, Rikke Ibsen, Ole Hilberg, Anders Løkke

  526-531

• Commentary to ‘Incidence of vestibular schwannoma in Finland, 1990–2017’ Pediatric vestibular schwannomas: an overlooked epidemiological aspect?

  Gabriele Gaggero

  466-467

• Relative risk of second malignant neoplasms highest among young adult cancer patients – a population-based registry study in Finland

  Hanna A.M. Koivisto, Aapeli O. Nevala, Joonas M. Miettinen, Janne M. Pitkäniemi, Nea K. Malila, Sanna M.M. Heikkinen

  418-425

• Evaluation of sex inequity in lung-cancer-specific survival

  Dan Lærum, Trond-Eirik Strand, Odd Terje Brustugun, Frode Gallefoss, Ragnhild Falk, Michael T. Durheim, Lars Fjellbirkeland

  343-350

• Progress against lung cancer, Denmark, 2008–2022

  Marianne Steding-Jessen, Henriette Engberg, Erik Jakobsen, Torben Riis Rasmussen, Henrik Møller

  339-342

• Anticancer therapy at end-of-life: A retrospective cohort study

  Johnny Singh, Andreas Stensvold, Martin Turzer, Ellen Karine Grov

  313-321

• TNM stage in the Nordic Cancer Registries 2004–2016: Registration and availability

  Gerda Engholm, Frida E. Lundberg, Simon M. Kønig, Elínborg Ólafsdóttir, Tom B. Johannesen, David Pettersson, Nea Malila, Lina S. Mørch, Anna L.V. Johansson, Søren Friis

  303-312

• Treatment-related mortality among children with cancer in Denmark during 2001-2021

  Marie C.L. Sørensen, Mie M. Andersen, Klaus Rostgaard, Kjeld Schmiegelow, Torben S. Mikkelsen, Peder S. Wehner, Marianne Olsen, Signe H. Søegaard, Lisa L. Hjalgrim

  294-302

• Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice

  Tobias Berg, Maj-Britt Jensen, Maria Rossing, Christian T. Axelsen, Iben Kümler, Lise Søndergaard, Marianne Vogsen, Ann S. Knoop, Bent Ejlertsen

  277-287

• Increased cancer incidence among patients with hidradenitis suppurativa – a Danish nationwide register study 1977–2017

  Rune Andersen, Klaus Rostgaard, Ole Pedersen, Gregor Borut Ernst Jemec, Henrik Hjalgrim

  220-228

• Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021

  Anna L.V. Johansson, Simon M. Kønig, Siri Larønningen, Gerda Engholm, Niels Kroman, Karri Seppä, Nea Malila, Bjarni Á. Steig, Eva Maria Gudmundsdóttir, Elínborg J. Ólafsdóttir, Frida E. Lundberg, Therese M.-L. Andersson, Paul C. Lambert, Mats Lambe, David Pettersson, Bjarte Aagnes, Søren Friis, Hans Storm

  179-191

• Area-based disparities in non-small-cell lung cancer survival

  Nelly-Maria Paakkola, Antti Jekunen, Eero Sihvo, Mikael Johansson, Heidi Andersén

  146-153

• Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study

  Martin Støyten, Tore Knutsen, Einar Stikbakke, Ingvild Agledahl, Tom Wilsgaard, Anne Elise Eggen, Elin Richardsen, Edward Giovannucci, Inger Thune, Hege S. Haugnes

  154-163

• Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study

  Sara Ekberg, Daniel Molin, Simon Pahnke, Fanny Bergström, Elsa Brånvall, Karin E. Smedby, Tove Wästerlid

  164-168

• Incidence of vestibular schwannoma in Finland, 1990–2017

  Aino Iivanainen, Jani Raitanen, Anssi Auvinen

  111-117

• Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer

  Frida E Lundberg, David Robinson, Ola Bratt, Giuseppe Fallara, Mats Lambe, Anna L. V. Johansson

  95-104

• Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study

  Erlend Skaga, Cassia B. Trewin-Nybråten, Pitt Niehusmann, Tom Børge Johannesen, Kirsten Marienhagen, Leif Oltedal, Stephanie Schipman, Anne Jarstein Skjulsvik, Ole Solheim, Tora Skeidsvoll Solheim, Terje Sundstrøm, Einar O. Vik-Mo, Petter Brandal, Tor Ingebrigtsen

  83-94

• Epidemiology of mastocytosis: a population-based study (Sweden)

  Anna Bergström, Hans Hägglund, Anders Berglund, Gunnar Nilsson, Mats Lambe

  44-50

• Blood sampling patterns in primary care change several years before a cancer diagnosis

  Mathilde Egelund Christensen, Mia Klinten Grand, Margit Kriegbaum, Bent Struer Lind, Kirsten Grønbæk, Frederik Persson, Christoffer Johansen, Christen Lykkegaard Andersen

  17-22

• Childhood cancer incidence and survival in the Faroe Islands, 1960 to 2019

  Marnar Fríðheim Kristiansen, Elmar Ósá, Lisa Lyngsie Hjalgrim, Bjarni á Steig, Guðrið Andórsdóttir, Marin Strøm, Maria Skaalum Petersen

  4-8